Methadone maintenance treatment and cognitive function: A systematic review

Current Drug Abuse Reviews

Volumn 6, Issue 3, 2013, Pages 220-230

  Wang, Grace Y ^a   Wouldes, Trecia A ^a   Russell, Bruce R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cognition; Methadone maintenance; Neuropsychological test; Opiate dependence; Systematic review

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE; PLACEBO;

ADAPTATION; COGNITION; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; LEARNING; LOW DRUG DOSE; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOMOTOR ACTIVITY; REVIEW; SUBSTANCE ABUSE; SYSTEMATIC REVIEW (TOPIC); WORKING MEMORY; CHEMICALLY INDUCED; COGNITIVE DEFECT; DOSE RESPONSE; DRUG EFFECTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TIME;

COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TIME FACTORS;

EID: 84899626604     PISSN: 18744737     EISSN: 18744745     Source Type: Journal    
DOI: 10.2174/18744737112059990020     Document Type: Review

References (74)

1. Gruber SA, Silveri MM, Yurgelun-Todd DA. Neuropsychological Consequences of Opiate Use Neuropsychology Review. 2007; 17(3): 299-315.
2. Garrido MJ, Trocóniz IF. Methadone: a review of its pharmacokinetic/pharmacodynamic properties. Journal of Pharmacological and Toxicological Methods. 1999; 42(2): 61-6.
3. Stimmel B, Kreek M. Neurobiology of addictive behaviors and its relationship to methadone maintenance Mount Sinai Journal of Medicine. 2000 67(5-6): 375-80.
4. Kreek MJ, Borg L, Ducat E, Ray B. Pharmacotherapy in the Treatment of Addiction: Methadone Journal of Addictive Diseases. 2010; 29: 200-16
5. Borg L, Ho A, Peters JE, Kreek MJ. Availability of reliable serum methadone determination for management of symptomatic patients Journal of Addictive Diseases. 1995; 14(3): 83-96.
6. Joseph R, Moselhy HF. National survey of methadone prescribing for maintenance treatment: 'opiophobia' among substance misuse services? Psychiatric Bulletin. 2005; 29, 459-461.
7. Holmstrand J, Anggard E, Gunne L. Methadone maintenance: plasma levels and therapeutic outcome. Clinical Pharmacology Therapy. 1978; 23: 175-80.
8. Tennant F, Rawson R, Cohen A, Traver A, Clabough D. Methadone plasma levels and persistent drug abuse in high dose methadone patients. Substance Alcohol Actions Misuse. 1983; 4: 369-74.
9. Payte J, Zweben J, Martin J, editors. Opioid maintenance treatment. Chevy Chase, MD: American Society of Addiction Medicine; 2003.
10. Leavitt S, Shinderman M, Maxwell S, Eap C, Paris P. When "enough" is not enough: new perspectives on optimal methadone maintenance dose. Mt SinaiJ Med. 2000; 67(5-6): 404-411.
11. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis Addiction. 1998; 93(4): 515-32.
12. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS. 1999 13(14): 1807-18.
13. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the Risk of AIDS Through Methadone Maintenance Treatment Journal of Health and Social Behavior. 1988; 29(3): 214-26
14. James B, Wayne H, Karen B. Changes in criminal activity after entering methadone maintenance. British Journal of Addiction. 2006; 87(2): 251-8.
15. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment. 2007; 11(9): 1-171.
16. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. The Mount Sinai Journal of Medicine. 2000; 67(5-6): 347-64.
17. Sellman D. Improving treatment for people with addiction problems in Aotearoa New Zealand. Inaugural Professional Lecture Series. Christchurch: Christchurch School of Medicine and Health Sciences; 2006.
18. Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients. Drug and Alcohol Dependence. 2009; 99(1-3): 132-40.
19. AIHW. National Opioid Pharmacotherapy Statistics Annual Data collection: 2010 report. Canberra: AIHW2011.
20. Bauer LO. CNS recovery from cocaine, cocaine and alcohol, or opioid dependence: a P300 study. Clinical Neurophysiology. 2001; 112(8): 1508-15.
21. Ma N, Liu Y, Li N, Wang CX, Zhang H, Jiang XF, et al. Addiction related alteration in resting-state brain connectivity. NeuroImage. 2010 01; 49(1): 738-44.
22. Koob G. Neurobiology of addiction. In: Koob G, Moal ML, editors. Addiction Counseling Review. New York2004.
23. Eisch AJ, Harburg GC. Opiates, psychostimulants, and adult hippocampal neurogenesis: Insights for addiction and stem cell biology. Hippocampus. 2006; 16(3): 271-86.
24. Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ. Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology. 2006; 31(5): 1036-47.
25. Marvel C, Faulkner M, Strain E, Mintzer M, Desmond J. An fMRI Investigation of Cerebellar Function During Verbal Working Memory in Methadone Maintenance Patients. The Cerebellum. 2012; 11(1): 300-10.
26. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. International Journal of Epidemiology. 2007; 36(3): 666-76.
27. Lombardo WK, Lombardo B, Goldstein A. Cognitive functioning under moderate and low dosage methadone maintenance. International Journal of the Addictions. 1976; 11(3): 389-401.
28. Appel P, Gordon N. Digit-symbol performance in methadonetreated ex-heroin addicts. Am J Psychiatry. 1976; 133: 1337-40
29. Appel PW. Sustained Attention in Methadone Patients. Substance Use & Misuse. 1982; 17: 1313-27.
30. Ersche KD, Roiser JP, Clark L, London M, Robbins TW, Sahakian BJ. Punishment induces risky decision-making in methadonemaintained opiate users but not in heroin users or healthy volunteers. Neuropsychopharmacology. 2005 30(11): 2115-24.
31. Loeber S, Kniest A, Diehl A, Mann K, Croissant B. Neuropsychological functioning of opiate-dependent patients: A nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment. American Journal of Drug and Alcohol Abuse. 2008 September; 34(5): 584-93.
32. Mintzer MZ, Copersino ML, Stitzer ML. Opioid abuse and cognitive performance. Drug and Alcohol Dependence. 2005; 78(2): 225-30.
33. Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. Drug and Alcohol Dependence. 2002; 67(1): 41-51.
34. Pirastu R, Fais R, Messina M, Bini V, Spiga S, Falconieri D, et al. Impaired decision-making in opiate-dependent subjects: Effect of pharmacological therapies. Drug and Alcohol Dependence. 2006; 83(2): 163-8.
35. Prosser J, Cohen LJ, Steinfeld M, Eisenberg D, London ED, Galynker II. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug and Alcohol Dependence. 2006 01; 84(3): 240-7.
36. Prosser J, London E, Galynker I. Sustained attention in patients receiving and abstinent following methadone maintenance treatment for opiate dependence: performance and neuroimaging results. Drug & Alcohol Dependence. 2009; 104(3): 228-40.
37. Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone vs buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clinical Pharmacology. 2007; 7(5).
38. Rapeli P, Fabritius C, Kalska H, Alho H. Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals. Substance Abuse Treatment, Prevention, and Policy. 2009; 4(6): 1-15.
39. Rothenberg S, Meyer RE, Rauss B, Gross K. Performance differences between addicts and non-addicts. Psychopharmacology. 1977; 52(3): 299-306.
40. Specka M, Finkbeiner T, Lodemann E, Leifert K, Kluwig J, Gastpar M. Cognitive-motor performance of methadonemaintained patients. European Addiction Research. 2000; 6: 8-19.
41. Verdejo A, Toribio I, Orozco C, Puente KL, Perez-Garcia M. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug and Alcohol Dependence. 2005 01; 78(3): 283-8.
42. Rapeli P, Fabritius C, Kalska H, Alho H. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clinical Pharmacology. 2011; 11(1): 13.
43. Baewert A, Gombas W, Schindler SD, Peternell-Moelzer A, Eder H, Jagsch R, et al. Influence of peak and trough levels of opioid maintenance therapy on driving aptitude. European Addiction Research 13(3): 127-35. 2007.
44. Clair J, Martin L, Bond AJ, O'Ryan D, Davis P, Curran HV. An experimental study of aggressive and neutral interpretative bias in opiate-dependent and opiate-abstinent men. Journal of Psychopharmacology. 2009; 23(4): 428-35.
45. Curran HV, Bolton J, Wanigaratne S, Smyth C. Additional methadone increases craving for heroin: A double-blind, placebocontrolled study of chronic opiate users receiving methadone substitution treatment. Addiction. 1999; 94(5): 665-74.
46. Curran HV, Kleckham J, Bearn J, Strang J, Wanigaratne S. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: A dose-response study. Psychopharmacology. 2001; 154(2): 153-60.
47. Darke S, Sims J, McDonald S, Wickes W. Cognitive impairment among methadone maintenance patients. Addiction. 2000; 95(5): 687-95.
48. Gruber SA, Tzilos GK, Silveri MM, Pollack M, Renshaw PF, Kaufman MJ, et al. Methadone maintenance improves cognitive performance after two months of treatment. Experimental & Clinical Psychopharmacology. 2006 May; 14(2): 157-64.
49. Kelley D, Welch R, McKnelley W. Methadone maintenance: An assessment of potential fluctuations in behavior between doses. International Journal of the Addictions. 1978; 13(7): 1061-8.
50. Kornreich C, Foisy M-L, Philippot P, Dan B, Tecco J, Noel X, et al. Impaired emotional facial expression recognition in alcoholics, opiate dependence subjects, methadone maintained subjects and mixed alcohol-opiate antecedents subjects compared with normal controls. Psychiatry Research. 2003; 119(3): 251-60.
51. Lyvers M, Yakimoff M. Neuropsychological correlates of opioid dependence and withdrawal. Addictive Behaviors. 2003; 28(3): 605-11.
52. Schindler SD, Ortner R, Peternell A, Eder H, Opgenoorth E, Fischer G. Maintenance therapy with synthetic opioids and driving aptitude. European Addiction Research. 2004; 10(2): 80-7.
53. Soyka M, Lieb M, Kagerer S, Zingg C, Koller G, Lehnert P, et al. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. Journal of Clinical Psychopharmacology. 2008; 28(6): 699-703.
54. Soyka M, Zingg C, Koller G, Hennig-Fast K. Cognitive function in short-and long-term substitution treatment: Are there differences? World Journal of Biological Psychiatry. 2009; First published on: 17 June 2009 (iFirst).
55. Soyka M, Limmer C, Lehnert R, Koller G, Martin G, Küfner H, et al. A Comparison of Cognitive Function in Patients under Maintenance Treatment with Heroin, Methadone, or Buprenorphine and Healthy Controls: An Open Pilot Study. The American Journal of Drug and Alcohol Abuse. 2011; 37(6): 497-508.
56. Nejati M, Nejati V, Mohammadi MR. Selective Attention and Drug Related Attention Bias in Methadone Maintenance Patients. Acta Medica Iranica. 2011; 49(12): 814-7.
57. Fadardi JS, Ziaee SS. A comparative study of drug-related attentional bias: Evidence from Iran. Experimental and Clinical Psychopharmacology. 2010; 18(6): 539-45.
58. Gritz ER, Shiffman SM, Jarvik ME, Haber J, Dymond AM, Coger R, et al. Physiological and psychological effects of methadone in man. Archives of General Psychiatry. 1975; 32(2): 237-42.
59. Grevert P, Masover B, Goldstein A. Failure of methadone and levomethadyl acetate (levo-alpha-acetylmethadol, LAAM) maintenance to affect memory. Archives of General Psychiatry. 1977 Jul; 34(7): 849-53.
60. Gordon NB. Reaction-times of methadone treated ex heroin addicts Psychopharmacology. 1970; 16: 337-44.
61. Davis PE, Liddiard H, McMillan TM. Neuropsychological deficits and opiate abuse. Drug and Alcohol Dependence. 2002; 67(1): 105-8.
62. Rapeli P, Fabritius C, Alho H, Salaspuro M, Wahlbeck K, Kalska H. Methadone vs buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clinical Pharmacology. 2007; 7: 5.
63. Ersche KD, Fletcher PC, Lewis SJ, Clark L, Stocks-Gee G, London M, et al. Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals. Psychopharmacology. 2005; 180(4): 612-23.
64. World Health Organization. Guidelines on methadone therapy in Myanmar for prescribers and dispensers. Ministry of Health; 2004.
65. Liu J, Liao X, Gong Z, Qin B. The difference between methadone and morphine in regulation of δ-opioid receptors underlies the antagonistic effect of methadone on morphine-mediated cellular actions. European Journal of Pharmacology. 1999; 373(2-3): 233-9.
66. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. Journal of Pharmacology and Experimental Therapeutics. 1991; 258(1): 299-303.
67. Fundytus ME, Schiller PW, Shapiro M, Weltrowska G, Coderre TJ. Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[ψ]. European Journal of Pharmacology. 1995; 286(1): 105-8.
68. Sankararaman A, Masiulis I, Richardson DR, Andersen JM, Mørland J, Eisch AJ. Methadone does not alter key parameters of adult hippocampal neurogenesis in the heroin-naïve rat. Neuroscience Letters. 2012; 516(1): 99-104.
69. Drapeau E, Mayo W, Aurousseau C, Le Moal M, Piazza P-V, Abrous DN. Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proceedings of the National Academy of Sciences. 2003; 100(24): 14385-90.
70. Kramer L, Bauer E, Funk G, Hofer H, Jessner W, Steindl-Munda P, et al. Subclinical impairment of brain function in chronic hepatitis C infection. Journal of Hepatology. 2002; 37(3): 349-54.
71. Gonzalez R, Jacobus J, Amatya AK, Quartana PJ, Vassileva J, Martin EM. Deficits in complex motor functions, despite no evidence of procedural learning deficits, among HIV+ individuals with history of substance dependence. Neuropsychology. 2008; 22(6): 776-86.
72. Avants SK, Margolin A, McMahon TJ, Kosten TR. Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadonemaintained patients. Addictive Behaviors. 1997; 22(5): 599-611.
73. Mintzer MZ. Effects of opioid pharmacotherapy on psychomotor and cognitive performance: A review of human laboratory studies of methadone and buprenorphine. Heroin Addiction and Related Clinical Problems. 2007; 9(1): 5-24.
74. MacDonald G. Social care: rhetorlc and reallty. In: Aviess D, Nutley M, Smith PC, editors. What works?: evidence-based policy and practice in public services The Great Britain: The Policy Press; 2000. p. 117-40.